REDUCE-IT study results showed an approximately 25% reduction in CV events with icosapent ethyl in patients with established CVD, diabetes and other risk factors, and raised LDL-cholesterol and triglycerides despite statin therapy. Further analyses discussed by Dr Gabriel Steg have demonstrated robust benefits for other endpoints, and that benefits correlated with achieved EPA levels, independent of changes in LDL-C, hs-CRP or TGs.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
